Stamford, CT (Press Release) – Spring­Works Thera­peutics, Inc. (Nasdaq: SWTX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,590,087 (the ‘087 patent), directed to niro­gace­stat, the Com­pany’s lead prod­uct can­di­date in devel­op­ment for patients with desmoid tumors and as a com­bi­na­tion ther­apy for patients with multiple myeloma. The ‘087 patent, assigned to Pfizer, Inc., expires in 2039. The ‘087 patent is a composition of matter patent that covers the polymorphic form of niro­gace­stat that is cur­rently in clin­i­cal devel­op­ment. Spring­Works has ex­clu­sive rights to the …

European Patent EP3004337 Upheld by the EPO in Favor of Cellectis, Refers to the Method of Preparing T-Cells for Immunotherapy Using the RNA-Guided CRISPR-Cas9 Nuclease System

New York, NY (Press Release) – Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a bio­pharma­ceu­tical com­pany focused on devel­op­ing immuno­therapies based on gene-edited allo­geneic CAR T-cells (UCART), today announced that European Patent EP3004337, which claims a method of preparing T-cells for immuno­therapy using the CRISPR-Cas9 sys­tem, initially granted on August 2, 2017, has been upheld by the European Patent Office (EPO) fol­low­ing an op­po­si­tion pro­ce­dure ini­ti­ated in May 2018.

European Patent EP3004337 claims a method of genetically modifying T-cells by in­tro­duc­tion into the cells and/or ex­pres­sion in the cells of an RNA-guided endonuclease, and …

Hyderabad, India (Press Release) – NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that it has reached a Settlement Agreement with Onyx Thera­peutics, Inc. on patent lit­i­ga­tion related to generic versions of 10mg, 30mg and 60mg of Kyprolis®. NATCO has partnered with Breckenridge Pharma­ceu­tical, Inc., who will mar­ket the prod­uct in the United States.

The parties have reached a Settlement Agreement and the District Court case has been dismissed. By virtue of the settlement, NATCO and Breckenridge have been granted a license permitting the launch of their generic car­filz­o­mib prod­uct …

Stockholm, Sweden (Press Release) – Oncopeptides AB (Nasdaq Stockholm: ONCO) to­day an­nounced that the US pat­ent and trademark office has issued a notice that they in­tend to grant addi­tional pat­ents to Oncopeptides AB in the US. Oncopeptides has pre­vi­ously re­ceived the corresponding pat­ent pro­tec­tion both in Japan and Europe.

These pat­ents (application numbers 14/438473 and 15/225323) pro­tect, inter alia, the freeze-dried for­mu­la­tion. The pat­ent pro­tec­tion extends to 2033. The freeze-dried preparation with melflufen is in­tended to be mar­keted at a future ap­­prov­al.

"We have now approved for­mu­la­tion pat­ents in all major key mar­kets …

Key Patent Covers Manufacture of Thera­peutic Products Containing a High Percentage of T Stem Cell Memory Cells

San Diego, CA (Press Release) – Poseida Thera­peutics Inc., a clin­i­cal-stage bio­pharma­ceu­tical com­pany leveraging pro­pri­e­tary non-viral gene engi­neer­ing tech­nolo­gies to create life-saving thera­peutics, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allow­ance for a patent pro­tecting the method of producing genetically modified T cells with a high per­cent­age of stem cell memory T cells (Tscm).

Tscm cells are long-lived, self-renewing and multipotent. These cells have the capacity to reconstitute the entire spectrum of effector and memory T cells subsets and usually sur­vive for decades and poten­tially …

Planegg / Munich, Germany (Press Release) – MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the dispute. As a result of this, the parties to the dispute have agreed to drop the mutual claims related to this lit­i­ga­tion.

On April 4, 2016 MorphoSys had filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. In 2017, a second …

• Genmab, Janssen and MorphoSys have agreed to end the patent infringement lawsuit launched by MorphoSys AG relating to DARZALEX
• On Jan­u­ary­ 25, 2019, a summary judge­ment de­ci­sion ruled that the three MorphoSys patents were invalid
• As a result of the agree­ment, MorphoSys will not appeal the summary judge­ment of invalidity and Genmab and Janssen will not pursue their inequitable conduct claim

Copenhagen, Denmark (Press Release) – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the patent infringement lawsuit launched by MorphoSys relating to DARZALEX® is finally over.

As pre­vi­ously reported, on Jan­u­ary­ 25, 2019, the U.S. District Court of the District of Delaware ruled that all three patents that MorphoSys had asserted against Genmab and Janssen Biotech, Inc. (Janssen) are invalid. As noted at that time, Genmab and Janssen’s alle­ga­tions that the patents were unenforceable for inequitable conduct remained to …